Published in Infect Immun on September 01, 1990
Tumour necrosis factor induction by malaria exoantigens depends upon phospholipid. Immunology (1992) 1.78
Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit tumour necrosis factor induction by malaria exoantigens. Immunology (1992) 1.23
In vivo induction of nitrite and nitrate by tumor necrosis factor, lymphotoxin, and interleukin-1: possible roles in malaria. Infect Immun (1992) 1.21
Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria. Clin Diagn Lab Immunol (2001) 1.10
Detoxified exoantigens and phosphatidylinositol derivatives inhibit tumor necrosis factor induction by malarial exoantigens. Infect Immun (1992) 1.10
Stimulation of nitric oxide production in macrophages by Babesia bovis. Infect Immun (1998) 1.09
Upregulation of ICAM-I by Plasmodium falciparum: in vitro and in vivo studies. J Clin Pathol (1994) 1.06
Changes in cytokine production associated with acquired immunity to Plasmodium falciparum malaria. Clin Exp Immunol (2001) 1.04
Malaria vaccine development. Clin Microbiol Rev (1994) 1.01
Bovine helper T cell clones recognize five distinct epitopes on Babesia bovis merozoite antigens. Infect Immun (1992) 1.01
Serological relationship of tumor necrosis factor-inducing exoantigens of Plasmodium falciparum and Plasmodium vivax. Infect Immun (1992) 1.01
Direct activation of human endothelial cells by Plasmodium falciparum-infected erythrocytes. Infect Immun (2005) 0.98
Production of interleukin-6 by human and murine mononuclear leukocytes stimulated with Plasmodium antigens is enhanced by pentoxifylline, and tumor necrosis factor secretion is reduced. Infect Immun (1993) 0.94
DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells. Infect Immun (1998) 0.89
Structural similarities among malaria toxins insulin second messengers, and bacterial endotoxin. Infect Immun (1996) 0.84
Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology (1993) 0.83
Ring-infected erythrocyte surface antigen (Pf/155RESA) induces tumour necrosis factor-alpha production. Clin Exp Immunol (1993) 0.81
Mast cell activation in the skin of Plasmodium falciparum malaria patients. Malar J (2015) 0.76
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science (1987) 7.01
Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med (1989) 6.79
Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum. Nature (1989) 5.62
Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry (1976) 5.43
Possible importance of macrophage-derived mediators in acute malaria. Infect Immun (1981) 3.58
Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med (1989) 3.32
Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol (1989) 3.09
Isolate-specific S-antigen of Plasmodium falciparum contains a repeated sequence of eleven amino acids. Nature (1984) 2.80
Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med (1988) 2.61
Cell-mediated immunity in protection and pathology of malaria. Parasitol Today (1987) 2.45
Malarial parasites induce TNF production by macrophages. Immunology (1988) 2.42
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
Soluble malarial antigens are toxic and induce the production of tumour necrosis factor in vivo. Immunology (1989) 1.77
The malaria vaccine: anti-parasite or anti-disease? Immunol Today (1990) 1.74
Characteristics of the protective response of BALB/c mice immunized with a purified Plasmodium yoelii schizont antigen. Clin Exp Immunol (1983) 1.69
Localization, biosynthesis, processing and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium falciparum. Mol Biochem Parasitol (1987) 1.49
Immunoadsorbent isolation of antigens from the culture medium of in vitro cultivated Plasmodium falciparum. Acta Pathol Microbiol Scand C (1981) 1.43
Human and murine macrophages produce TNF in response to soluble antigens of Plasmodium falciparum. Parasite Immunol (1990) 1.40
Cellular immune responses to Plasmodium falciparum antigens in Gambian children during and after an acute attack of falciparum malaria. Clin Exp Immunol (1988) 1.36
Malaria exoantigens induce T-independent antibody that blocks their ability to induce TNF. Immunology (1990) 1.35
Vaccination of mice against malaria with soluble antigens. I. The effect of detergent, route of injection, and adjuvant. Parasite Immunol (1986) 1.20
Antigens and antibodies in Plasmodium falciparum malaria studied by immunoelectrophoretic methods. Acta Pathol Microbiol Scand C (1980) 1.18
Tumor necrosis factor production by human macrophages stimulated in vitro by Plasmodium falciparum. Infect Immun (1990) 1.14
Cell-mediated immune responses to Plasmodium falciparum antigens in adult Gambians. Clin Exp Immunol (1988) 1.14
Demonstration of soluble Plasmodium falciparum antigens reactive with Limulus amoebocyte lysate and polymyxin B. Parasite Immunol (1988) 1.10
Soluble Plasmodium falciparum antigens contain carbohydrate moieties important for immune reactivity. J Clin Microbiol (1987) 1.09
Induction of TNF in vitro as a model for the identification of toxic malaria antigens. Lymphokine Res (1989) 0.84
Inhibitory monoclonal antibodies to soluble Plasmodium falciparum antigens. Parasitol Res (1987) 0.78
Common west African HLA antigens are associated with protection from severe malaria. Nature (1991) 9.43
The cellular basis of immunological responses. A synthesis of some current views. Lancet (1969) 6.05
Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature (1995) 4.42
Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature (1994) 4.37
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
Association of malaria parasite population structure, HLA, and immunological antagonism. Science (1998) 3.40
A trial of artemether or quinine in children with cerebral malaria. N Engl J Med (1996) 3.28
Focal antibody production by transferred spleen cells in irradiated mice. Science (1965) 3.12
Neurological sequelae of cerebral malaria in children. Lancet (1990) 3.11
Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol (1989) 3.09
Strain differences in the immune response of mice. I. The neonatal response to sheep red cells. Immunology (1968) 2.98
Mena is required for neurulation and commissure formation. Neuron (1999) 2.94
A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet (1999) 2.83
Immunosuppression in murine malaria. I. General characteristics. Clin Exp Immunol (1971) 2.56
Spontaneous movements associated with rocuronium: is pain on injection the cause? Br J Anaesth (1997) 2.55
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax (2000) 2.49
Malarial parasites induce TNF production by macrophages. Immunology (1988) 2.42
The regulation of malaria parasitaemia: parameter estimates for a population model. Parasitology (1995) 2.36
Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum. Clin Exp Immunol (1984) 2.34
Endotoxin-induced serum factor kills malarial parasites in vitro. Infect Immun (1981) 2.30
Systemic cytokine response after major surgery. Br J Surg (1992) 2.23
Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol (1995) 2.19
Induction of red cell autoantibodies in normal mice. Nat New Biol (1973) 2.09
Malaria susceptibility and CD36 mutation. Nature (2000) 2.07
Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J Cell Biol (2000) 2.07
Rosette formation in Plasmodium falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or uncomplicated malaria. Am J Trop Med Hyg (1992) 2.06
Protection of mice against malaria by a killed vaccine: differences in effectiveness against P. yoelii and P. berghei. Immunology (1977) 2.03
Immunosuppressive potency and in-vitro activity of antilymphocyte globulin. Lancet (1969) 2.02
Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg (1994) 1.96
1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun (1998) 1.96
Cell cooperation in the immune response. Clin Exp Immunol (1971) 1.91
HLA class I typing by PCR: HLA-B27 and an African B27 subtype. Lancet (1991) 1.86
Residual neurologic sequelae after childhood cerebral malaria. J Pediatr (1997) 1.84
Cell-mediated immunity in mice vaccinated against malaria. Clin Exp Immunol (1978) 1.82
Differential sensitivity in vivo of lethal and nonlethal malarial parasites to endotoxin-induced serum factor. Infect Immun (1982) 1.79
Suppressor T cells in experimental autoimmune haemolytic anaemia. Nature (1978) 1.79
Separate thymus dependent and thymus independent antibody forming cell precursors. Nat New Biol (1971) 1.78
Tumour necrosis factor induction by malaria exoantigens depends upon phospholipid. Immunology (1992) 1.78
Soluble malarial antigens are toxic and induce the production of tumour necrosis factor in vivo. Immunology (1989) 1.77
Killing of human malaria parasites by macrophage secretory products. Infect Immun (1984) 1.76
Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria. Infect Immun (1997) 1.75
Killing of blood-stage murine malaria parasites by hydrogen peroxide. Infect Immun (1983) 1.74
Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol (2000) 1.74
The malaria vaccine: anti-parasite or anti-disease? Immunol Today (1990) 1.74
The role of antibody in T-cell responses. Clin Exp Immunol (1974) 1.67
The role of the liver in immunity to blood-stage murine malaria. Immunology (1980) 1.65
Estimating sequestered parasite population dynamics in cerebral malaria. Proc Natl Acad Sci U S A (1998) 1.64
Cell-mediated immunity in the liver of mice vaccinated against malaria. Nature (1979) 1.64
The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis (1996) 1.62
Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro. Clin Exp Immunol (1987) 1.62
Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J Immunol (1999) 1.59
Rosette formation by mouse lymphocytes. III. Receptors for immunoglobulin on normal and activated T cells. Clin Exp Immunol (1974) 1.59
Parasite virulence and disease patterns in Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (1994) 1.57
Strain differences in the immune responses of mice. 3. A raised tolerance threshold in NZB thymus cells. Immunology (1971) 1.57
Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem (1998) 1.54
Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis (1999) 1.54
Specific tolerance to sheep erythrocytes in mouse bone marrow cells. Nature (1969) 1.52
Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. Lancet (1989) 1.50
Diversity of Plasmodium falciparum clones infecting children living in a holoendemic area in north-eastern Tanzania. Acta Trop (2002) 1.49
Expression and rescuing of a cloned human tumour necrosis factor gene using an EBV-based shuttle cosmid vector. EMBO J (1987) 1.48
Observations on the periodicity of Plasmodium falciparum gametocytes in natural human infections. Acta Trop (2000) 1.48
Response of mouse T and B lymphocytes to sheep erythrocytes. Nat New Biol (1972) 1.45
Strain differences in the immune response of mice. II. Responses by neonatal cells in irradiated adult hosts. Immunology (1968) 1.45
Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis (1998) 1.44
Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet (2001) 1.43
Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. Clin Exp Immunol (1987) 1.42
Evidence of endothelial inflammation, T cell activation, and T cell reallocation in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (1994) 1.42
Response to phytohaemagglutinin of lymphocytes from mice treated with anti-lymphocyte globulin. Immunology (1969) 1.41
Human and murine macrophages produce TNF in response to soluble antigens of Plasmodium falciparum. Parasite Immunol (1990) 1.40
Rosette formation by mouse lymphocytes. II. T-cell specificities in a CRL subpopulation. Clin Exp Immunol (1974) 1.39
Indirect immunofluorescence of mouse thymus-derived cells using heterologous anti-brain serum. Cell Immunol (1973) 1.38
Reactivity and crossreactivity of mouse helper T cells to malaria parasites. Immunology (1977) 1.36
Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia. Am J Hum Genet (1992) 1.35
Malaria exoantigens induce T-independent antibody that blocks their ability to induce TNF. Immunology (1990) 1.35
Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet (1998) 1.35
Killing of the malarial parasite Plasmodium yoelii in vitro by cells of myeloid origin. Parasite Immunol (1982) 1.34
Immunity to malaria. Br Med Bull (1982) 1.34
Antibody responses in mice protected against malaria by vaccination. Parasite Immunol (1979) 1.34
Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS (1996) 1.32
Antibody formation by bone marrow cells in irradiated mice. I. Thymus-dependent and thymus-independent responses to sheep erythrocytes. Immunology (1971) 1.31
Syngeneic splenomegaly in NZB and BALB-c mice. Transplantation (1969) 1.30
Analysis of IL10 haplotypic associations with severe malaria. Genes Immun (2005) 1.29
Tumour necrosis factor-dependent parasite-killing effects during paroxysms in non-immune Plasmodium vivax malaria patients. Clin Exp Immunol (1992) 1.29
Morbidity from malaria and immune responses to defined Plasmodium falciparum antigens in children with sickle cell trait in The Gambia. Trans R Soc Trop Med Hyg (1993) 1.28
Spontaneously arising cytotoxicity to the P-815-Y mastocytoma in NZB mice. Clin Exp Immunol (1974) 1.27
Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis (1997) 1.27
Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa. Genes Immun (2001) 1.25
The genetic basis of autoimmunity in NZB mice studied by progeny-testing. Clin Exp Immunol (1971) 1.24
Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit tumour necrosis factor induction by malaria exoantigens. Immunology (1992) 1.23
Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res (1988) 1.22
Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. Trans R Soc Trop Med Hyg (1998) 1.21
Vaccination of mice against malaria with soluble antigens. I. The effect of detergent, route of injection, and adjuvant. Parasite Immunol (1986) 1.20
Cellular basis of early cytokine response to Plasmodium falciparum. Infect Immun (2001) 1.20
Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304. Proc Natl Acad Sci U S A (1992) 1.20
Anaemia and resistance to malaria in transgenic mice expressing human tumour necrosis factor. Immunology (1994) 1.19
Plasmodium falciparum varies in its ability to induce tumor necrosis factor. Infect Immun (1993) 1.19
Rosette formation by mouse lymphocytes. I. Demonstration by indirect immunofluorescence of T cells binding sheep erythrocytes. Clin Exp Immunol (1974) 1.17
Loss of cellular immune reactivity during acute Plasmodium falciparum malaria. FEMS Microbiol Immunol (1991) 1.15